Ksart HCT 300/25 - All You Need To Know In 2021
1 December 2021

Ksart HCT 300/25


What it is used for

IRBESARTAN HCT MEDIS is indicated for the treatment of hypertension. Treatment should not be initiated with this fixed dose combination.


How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

  • Store below 25 degrees Celsius
  • Protect from Light
  • Shelf lifetime is 36 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems


How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

  • Store below 25 degrees Celsius
  • Protect from Light
  • Shelf lifetime is 36 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Pregnant or planning a pregnancy?

For the active ingredient irbesartan + hydrochlorothiazide

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.


Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.


Visual appearance

white, oblong, biconvex tablets embossed 1H25 on one side


Is this medicine subsidised?

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2020. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.

Ben

Read Previous

Kripton

Read Next

Kuvan

0 0 votes
Do you use this medicine? Rate it:
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments